A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
Full data from the Helios-A trial support vutrisiran’s profile as a more convenient Onpattro, though that’s probably as good as it gets.
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Key catalysts approach for Orphazyme, Gemini and Immutep.